LEETRO
430425
LAISAI LASER
871263
TIETUO MACHINERY
873706
4
Geovis Insighter Technology
920116
5
Beijing Global Safety Technology
300523
US Stock MarketDetailed Quotes
SWTX SpringWorks Therapeutics
- 51.380
- -1.900-3.57%
Close Mar 4 16:00 ET
- 51.500
- +0.120+0.23%
Post 19:56 ET
3.85BMarket Cap-14.76P/E (TTM)
53.600High51.270Low2.06MVolume52.790Open53.280Pre Close106.76MTurnover2.79%Turnover RatioLossP/E (Static)74.94MShares62.00052wk High8.00P/B3.79BFloat Cap28.21052wk Low--Dividend TTM73.76MShs Float96.480Historical High--Div YieldTTM4.37%Amplitude13.600Historical Low51.809Avg Price1Lot Size
Trending Stocks
Discussing
Trump 2.0 Era: How will global markets evolve?
🎙️Discussion: 1. How will tariff policies affect the movement of key assets such as U.S. stocks, gold, and Bitcoin? 2. Given this context,
Moo Live
Jan 23 16:54
MicroStrategy Q4 2024 earnings conference call
SpringWorks Therapeutics Stock Forum
Can SpringWorks' Dual Drug Strategy Transform Its Financial Future? Q4 Results Reveal Key Insights
Historic FDA Approval: Groundbreaking NF1-PN Treatment Shows Remarkable 52% Response in Children
Breakthrough FDA Approval: New Drug Shows Remarkable 52% Response Rate in Children with Rare Tumor Disease
FDA: Approved Mirdametinib, for Adult & Pediatric Patients 2 Years of Age & Older With Nf1 Who Have Symptomatic Pn Not Amenable to Complete Resection
-Billionaire investor Stanley Druckenmiller told Bloomberg on Wednesday that selling all his Nvidia stock this year was a “big mistake.”
-Nvidia was Druckenmiller's top holding a year ago, but he sold it after the stock tripled in 2023.
-The shares are up another 174% this year, and Druckenmiller has missed much of the continuing rally.
Stanley Druckenmiller is an American billionair...
$Iovance Biotherapeutics (IOVA.US)$ Phase 2
$Supernus Pharmaceuticals (SUPN.US)$ Phase 2a
$BRANDES INTERNATIONAL ETF (BINV.US)$ Phase 2a
$MorphoSys (MOR.US)$ Phase 2
$Nuvation Bio (NUVB.US)$ Phase 2
$ALX Oncology (ALXO.US)$ Phase 2
$BioXcel Therapeutics (BTAI.US)$ Phase 2
$Purple Biotech (PPBT.US)$ Phase 2
$Arcus Biosciences (RCUS.US)$ Phase 2
$Medicenna Therapeutics (MDNAF.US)$ Phase 2b
$Affimed NV (AFMD.US)$ Phase 2
$Barinthus Biotherapeutics (BRNS.US)$ Phase 2b...
» Holdings in Top 20: 58.46%
» Qtr over Qtr Change**: 28.47%
Top Holdings:
$Cerevel Therapeutics Holdings (CERE.US)$
$Amicus Therapeutics (FOLD.US)$
$Iovance Biotherapeutics (IOVA.US)$
$Arcellx (ACLX.US)$
$Nuvalent (NUVL.US)$
$Apogee Therapeutics (APGE.US)$
$Inhibrx (INBX.US)$
$Fusion Pharmaceuticals (FUSN.US)$
$Rhythm Pharmaceuticals (RYTM.US)$
$Vaxcyte (PCVX.US)$
$Soleno Therapeutics (SLNO.US)$
$Medtronic (MDT.US)$
$Madrigal Pharmaceuticals (MDGL.US)$
...
⇨ held by 5 biopharma-focused hedge funds! 🔥
$Arcellx (ACLX.US)$ : Anito-cel (Ph 2)
$Adaptimmune Therapeutics (ADAP.US)$ : Afami-cel (PDUFA) ⏳
$Bicycle Therapeutics (BCYC.US)$ : BT8009 (Ph 1/2)
$Centessa Pharmaceuticals (CNTA.US)$ : LB101 (Ph 1/2)
$Day One Biopharmaceuticals (DAWN.US)$ : Tovorafenib (PDUFA) (check comments for details)
$Fate Therapeutics (FATE.US)$ : FT576 (Ph 1)
$Fusion Pharmaceuticals (FUSN.US)$ : FPI-2265 (Ph 2)
$GRCL: ...
No comment yet